338 related articles for article (PubMed ID: 14615365)
1. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia.
Harada H; Harada Y; Niimi H; Kyo T; Kimura A; Inaba T
Blood; 2004 Mar; 103(6):2316-24. PubMed ID: 14615365
[TBL] [Abstract][Full Text] [Related]
2. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia.
Harada H; Harada Y; Tanaka H; Kimura A; Inaba T
Blood; 2003 Jan; 101(2):673-80. PubMed ID: 12393679
[TBL] [Abstract][Full Text] [Related]
3. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21.
Preudhomme C; Warot-Loze D; Roumier C; Grardel-Duflos N; Garand R; Lai JL; Dastugue N; Macintyre E; Denis C; Bauters F; Kerckaert JP; Cosson A; Fenaux P
Blood; 2000 Oct; 96(8):2862-9. PubMed ID: 11023523
[TBL] [Abstract][Full Text] [Related]
4. Point mutations in the AML1/RUNX1 gene associated with myelodysplastic syndrome.
Harada H; Harada Y
Crit Rev Eukaryot Gene Expr; 2005; 15(3):183-96. PubMed ID: 16390315
[TBL] [Abstract][Full Text] [Related]
5. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
6. Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.
Harada H; Harada Y; Kimura A
Curr Cancer Drug Targets; 2006 Sep; 6(6):553-65. PubMed ID: 17017876
[TBL] [Abstract][Full Text] [Related]
7. Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.
Steensma DP; Gibbons RJ; Mesa RA; Tefferi A; Higgs DR
Eur J Haematol; 2005 Jan; 74(1):47-53. PubMed ID: 15613106
[TBL] [Abstract][Full Text] [Related]
8. AML1 mutations induced MDS and MDS/AML in a mouse BMT model.
Watanabe-Okochi N; Kitaura J; Ono R; Harada H; Harada Y; Komeno Y; Nakajima H; Nosaka T; Inaba T; Kitamura T
Blood; 2008 Apr; 111(8):4297-308. PubMed ID: 18192504
[TBL] [Abstract][Full Text] [Related]
9. Aml1 gene rearrangements and mutations in radiation-associated acute myeloid leukemia and myelodysplastic syndromes.
Klymenko S; Trott K; Atkinson M; Bink K; Bebeshko V; Bazyka D; Dmytrenko I; Abramenko I; Bilous N; Misurin A; Zitzelsberger H; Rosemann M
J Radiat Res; 2005 Jun; 46(2):249-55. PubMed ID: 15988144
[TBL] [Abstract][Full Text] [Related]
10. New mechanisms of AML1 gene alteration in hematological malignancies.
Roumier C; Fenaux P; Lafage M; Imbert M; Eclache V; Preudhomme C
Leukemia; 2003 Jan; 17(1):9-16. PubMed ID: 12529654
[TBL] [Abstract][Full Text] [Related]
11. High frequency of AML1/RUNX1 point mutations in radiation-associated myelodysplastic syndrome around Semipalatinsk nuclear test site.
Zharlyganova D; Harada H; Harada Y; Shinkarev S; Zhumadilov Z; Zhunusova A; Tchaizhunusova NJ; Apsalikov KN; Kemaikin V; Zhumadilov K; Kawano N; Kimura A; Hoshi M
J Radiat Res; 2008 Sep; 49(5):549-55. PubMed ID: 18724045
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
13. Novel loss-of-function mutations of the haematopoiesis-related transcription factor, acute myeloid leukaemia 1/runt-related transcription factor 1, detected in acute myeloblastic leukaemia and myelodysplastic syndrome.
Nakao M; Horiike S; Fukushima-Nakase Y; Nishimura M; Fujita Y; Taniwaki M; Okuda T
Br J Haematol; 2004 Jun; 125(6):709-19. PubMed ID: 15180860
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutations.
Harada Y; Harada H
J Cell Biochem; 2011 Feb; 112(2):425-32. PubMed ID: 21268063
[TBL] [Abstract][Full Text] [Related]
15. Mutational analyses of the AML1 gene in patients with myelodysplastic syndrome.
Imai O; Kurokawa M; Izutsu K; Hangaishi A; Maki K; Ogawa S; Chiba S; Mitani K; Hirai H
Leuk Lymphoma; 2002 Mar; 43(3):617-21. PubMed ID: 12002768
[TBL] [Abstract][Full Text] [Related]
16. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation.
Christiansen DH; Andersen MK; Pedersen-Bjergaard J
Blood; 2004 Sep; 104(5):1474-81. PubMed ID: 15142876
[TBL] [Abstract][Full Text] [Related]
17. Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis.
Imai Y; Kurokawa M; Izutsu K; Hangaishi A; Takeuchi K; Maki K; Ogawa S; Chiba S; Mitani K; Hirai H
Blood; 2000 Nov; 96(9):3154-60. PubMed ID: 11049997
[TBL] [Abstract][Full Text] [Related]
18. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.
Osato M
Oncogene; 2004 May; 23(24):4284-96. PubMed ID: 15156185
[TBL] [Abstract][Full Text] [Related]
19. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies.
Taketani T; Taki T; Takita J; Tsuchida M; Hanada R; Hongo T; Kaneko T; Manabe A; Ida K; Hayashi Y
Genes Chromosomes Cancer; 2003 Sep; 38(1):1-7. PubMed ID: 12874780
[TBL] [Abstract][Full Text] [Related]
20. Unlike AML1, CBFbeta gene is not deregulated by point mutations in acute myeloid leukemia and in myelodysplastic syndromes.
Leroy H; Roumier C; Grardel-Duflos N; Macintyre E; Lepelley P; Fenaux P; Preudhomme C
Blood; 2002 May; 99(10):3848-50. PubMed ID: 11986246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
